CGEM · Cullinan Therapeutics, Inc.

Cullinan Therapeutics announced its first quarter 2026 financial results alongside significant pipeline advancements, highlighting robust cash position and upcoming clinical catalysts. Cash and investments stood at $393.3 million as of March 31, 2026, down from $439.0 million at year-end 2025, supporting operations into 2029 under the current plan. R&D expenses rose slightly to $42.1 million from $41.5 million year-over-year, reflecting ongoing clinical investments, while G&A declined to $11.6 million from $13.5 million, contributing to a net loss of $49.7 million versus $48.5 million in Q1 2025. EPS for common stock was $(0.75), marginally wider than $(0.74) last year. CEO Nadim Ahmed emphasized T cell engagers' transformative potential in autoimmune diseases and cancer, with CD19 and BCMA targets validated. Key milestones include initial single-dose data for CLN-978 in SLE, RA, and SjD at EULAR 2026 on June 6, multi-dose RA data in Q3 2026, and velinotamig SLE data in Q4 2026 via partner Genrix Bio. In oncology, CLN-049 updates in H2 2026 aim for RP2D by Q4 for AML/MDS. A major regulatory win: FDA acceptance of partner Taiho's zipalertinib NDA for 2L EGFR ex20ins NSCLC, with PDUFA February 27, 2027, and potential $30 million milestone; 1L pivotal REZILIENT3 topline by end-2026 could unlock up to $100 million more plus 50/50 U.S. profit share. These catalysts position Cullinan for momentum amid high-unmet-need indications.